Eurofarma asks Brazil’s CADE to prohibit Celgene from preventing development, sales of generic Revlimid
Brazilian pharmaceutical company Eurofarma has asked the Brazilian competition authority to impose a preventive measure prohibiting Celgene from hindering the development and sale of generic medicines that compete with Celgene’s Revlimid....To view the full article, register now.
Already a subscriber? Click here to view full article